SOD1 and Parkinson disease: One such therapy, Tofersen, demonstrably decreases SOD1 protein synthesis [93] and thus may represent a viable treatment option for Parkinson disease where enhanced wild-type SOD1 synthesis appears to contribute to the formation of disSOD1 pathology.